Adult T-Cell Leukemia/Lymphoma: Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission.
The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Similar to the first-line setting, standard treatment for relapsed/refractory ATLL has not been established. Many chemotherapy regimens used to treat other T-cell lymphomas following a relapse are also being used to treat ALL, including the following:
- DHAP (dexamethasone, cytarabine and cisplatin)
- ESHAP (detoposide, methylprednisolone, cytarabine and cisplatin)
- GDP (gemcitabine, dexamethasone and cisplatin)
- ICE (ifosfamide, carboplatin and etoposide)
To learn about treatments under investigation for ATLL, download the Adult T-Cell Leukemia/Lymphoma Fact Sheet.
Patients may also want to consider a clinical trial for relapsed/refractory ATLL. See also: Clinical Trials Fact Sheet.